Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free EKF Stock Alerts

EKF Diagnostics (EKF) Competitors

EKF Diagnostics logo
GBX 25 -1.00 (-3.85%)
As of 09/21/2026 12:00 PM Eastern
Compare

EKF vs. NIOX, TSTL, SPEC, CREO, and IUG

Should you buy EKF Diagnostics stock or one of its competitors? EKF Diagnostics's main competitors and comparable companies include NIOX Group (NIOX), Tristel (TSTL), INSPECS Group (SPEC), Creo Medical Group (CREO), and Intelligent Ultrasound Group (IUG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does EKF Diagnostics compare to NIOX Group?

NIOX Group (LON:NIOX) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, EKF Diagnostics had 3 more articles in the media than NIOX Group. MarketBeat recorded 5 mentions for EKF Diagnostics and 2 mentions for NIOX Group. EKF Diagnostics' average media sentiment score of 0.38 beat NIOX Group's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NIOX Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
EKF Diagnostics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are held by institutional investors. 5.1% of NIOX Group shares are held by insiders. Comparatively, 40.2% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NIOX Group has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, indicating that its stock price is 50% less volatile than the broader market.

NIOX Group presently has a consensus target price of GBX 86, suggesting a potential upside of 28.36%. EKF Diagnostics has a consensus target price of GBX 35, suggesting a potential upside of 40.00%. Given EKF Diagnostics' higher possible upside, analysts clearly believe EKF Diagnostics is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

NIOX Group has higher earnings, but lower revenue than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NIOX Group£48.70M5.79£995.88M£1.6440.85
EKF Diagnostics£51.35M2.08£4.68M£0.4753.19

NIOX Group has a net margin of 14.37% compared to EKF Diagnostics' net margin of 4.86%. NIOX Group's return on equity of 10.14% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
NIOX Group14.37% 10.14% 3.95%
EKF Diagnostics 4.86%3.58%5.27%

Summary

EKF Diagnostics beats NIOX Group on 8 of the 14 factors compared between the two stocks.

How does EKF Diagnostics compare to Tristel?

Tristel (LON:TSTL) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

22.4% of Tristel shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 40.2% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.86%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
EKF Diagnostics 4.86%3.58%5.27%

In the previous week, EKF Diagnostics had 3 more articles in the media than Tristel. MarketBeat recorded 5 mentions for EKF Diagnostics and 2 mentions for Tristel. EKF Diagnostics' average media sentiment score of 0.38 beat Tristel's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tristel
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
EKF Diagnostics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tristel has higher earnings, but lower revenue than EKF Diagnostics. Tristel is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.88£6.54M£16.2424.64
EKF Diagnostics£51.35M2.08£4.68M£0.4753.19

EKF Diagnostics has a consensus price target of GBX 35, indicating a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe EKF Diagnostics is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tristel has a beta of 0.344, meaning that its stock price is 66% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, meaning that its stock price is 50% less volatile than the broader market.

Summary

EKF Diagnostics beats Tristel on 9 of the 16 factors compared between the two stocks.

How does EKF Diagnostics compare to INSPECS Group?

EKF Diagnostics (LON:EKF) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

EKF Diagnostics has a net margin of 4.86% compared to INSPECS Group's net margin of -0.52%. EKF Diagnostics' return on equity of 3.58% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.86% 3.58% 5.27%
INSPECS Group -0.52%-1.19%0.45%

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 0.2% of INSPECS Group shares are held by institutional investors. 40.2% of EKF Diagnostics shares are held by insiders. Comparatively, 19.6% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, EKF Diagnostics had 5 more articles in the media than INSPECS Group. MarketBeat recorded 5 mentions for EKF Diagnostics and 0 mentions for INSPECS Group. EKF Diagnostics' average media sentiment score of 0.38 beat INSPECS Group's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
EKF Diagnostics Neutral
INSPECS Group Neutral

EKF Diagnostics has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.35M2.08£4.68M£0.4753.19
INSPECS Group£193.23M0.53-£4.11M-£9.40N/A

EKF Diagnostics presently has a consensus target price of GBX 35, indicating a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe EKF Diagnostics is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

EKF Diagnostics has a beta of 0.499, indicating that its share price is 50% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, indicating that its share price is 60% more volatile than the broader market.

Summary

EKF Diagnostics beats INSPECS Group on 14 of the 16 factors compared between the two stocks.

How does EKF Diagnostics compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.86%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
EKF Diagnostics 4.86%3.58%5.27%

In the previous week, EKF Diagnostics had 5 more articles in the media than Creo Medical Group. MarketBeat recorded 5 mentions for EKF Diagnostics and 0 mentions for Creo Medical Group. EKF Diagnostics' average media sentiment score of 0.38 beat Creo Medical Group's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Creo Medical Group Neutral
EKF Diagnostics Neutral

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M9.87-£25.04M£1.0012.19
EKF Diagnostics£51.35M2.08£4.68M£0.4753.19

Creo Medical Group currently has a consensus price target of GBX 40, indicating a potential upside of 228.19%. EKF Diagnostics has a consensus price target of GBX 35, indicating a potential upside of 40.00%. Given Creo Medical Group's higher possible upside, equities research analysts clearly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Creo Medical Group has a beta of 1.563854, meaning that its share price is 56% more volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, meaning that its share price is 50% less volatile than the broader market.

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 7.0% of Creo Medical Group shares are owned by insiders. Comparatively, 40.2% of EKF Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

EKF Diagnostics beats Creo Medical Group on 9 of the 16 factors compared between the two stocks.

How does EKF Diagnostics compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

EKF Diagnostics has a net margin of 4.86% compared to Intelligent Ultrasound Group's net margin of -23.11%. EKF Diagnostics' return on equity of 3.58% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
EKF Diagnostics 4.86%3.58%5.27%

In the previous week, EKF Diagnostics had 5 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 5 mentions for EKF Diagnostics and 0 mentions for Intelligent Ultrasound Group. EKF Diagnostics' average media sentiment score of 0.38 beat Intelligent Ultrasound Group's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
EKF Diagnostics Neutral

EKF Diagnostics has a consensus target price of GBX 35, indicating a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe EKF Diagnostics is more favorable than Intelligent Ultrasound Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intelligent Ultrasound Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Intelligent Ultrasound Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, indicating that its stock price is 50% less volatile than the broader market.

EKF Diagnostics has higher revenue and earnings than Intelligent Ultrasound Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
EKF Diagnostics£51.35M2.08£4.68M£0.4753.19

75.5% of Intelligent Ultrasound Group shares are held by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are held by institutional investors. 12.8% of Intelligent Ultrasound Group shares are held by insiders. Comparatively, 40.2% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

EKF Diagnostics beats Intelligent Ultrasound Group on 14 of the 15 factors compared between the two stocks.

Get EKF Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EKF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EKF vs. The Competition

Export
MetricEKF DiagnosticsHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£107.04M£5.55B£7.26B£2.89B
Dividend Yield4.65%1.80%2.53%6.23%
P/E Ratio53.1925.32274.69366.69
Price / Sales2.0872.07696.4690,194.79
Price / Cash10.6433.1128.0427.89
Price / Book1.625.8810.566.37
Net Income£4.68M£151.55M£3.49B£5.89B
7 Day Performance-4.34%0.98%0.81%0.96%
1 Month Performance-1.57%-3.89%-2.80%-0.04%
1 Year Performance-13.79%5.91%16.69%19.41%

EKF Diagnostics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EKF
EKF Diagnostics
2.6967 of 5 stars		GBX 25
-3.8%		GBX 35
+40.0%		-16.7%£107.04M£51.35M53.19356
NIOX
NIOX Group
1.9385 of 5 stars		GBX 65
flat		GBX 86
+32.3%		-9.0%£273.56M£48.70M39.6392
TSTL
Tristel
N/AGBX 391
-0.4%		N/A+10.7%£187.97M£49.54M24.08208
SPEC
INSPECS Group
N/AGBX 92.63
-3.5%		GBX 60
-35.2%		+130.8%£101.12M£193.23MN/A1,673
CREO
Creo Medical Group
N/AGBX 12.40
0.0%		GBX 40
+222.6%		-0.1%£60.24M£6M12.40279

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:EKF) was last updated on 9/22/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Gold did this exact thing in 1975… [then exploded]
In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...
Golden Portfolio | Sponsoredtc pixel
A councilman backed AI — then 13 bullets hit his front door
Thirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...
Stansberry Research | Sponsoredtc pixel
NVDA CEO says it’s a "once-in-a-generation opportunity"
NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...
Monument Traders Alliance | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel